Drug intelligence / Profile preview

donepezil + scopolamine

Development stage
Unknown
Lead developer
Eisai
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

Donepezil + scopolamine is a combination of two pharmaceutical agents with opposing actions on the cholinergic system. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain, primarily used to treat cognitive symptoms of Alzheimer's disease and other dementias by enhancing cholinergic neurotransmission[3][5][6]. Scopolamine, also known as hyoscine, is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at muscarinic receptors, leading to anticholinergic effects such as sedation and memory impairment. This combination is not used therapeutically due to their antagonistic mechanisms; in fact, co-administration may reduce or negate the benefits of each drug[1]. In research settings, scopolamine is sometimes used to induce temporary cognitive deficits for testing potential cognition-enhancing drugs like donepezil[2][4][8].

Brand names
AriceptTransderm Scop
Other names
E2020 (donepezil)hyoscine (scopolamine)
02

Targets

mAChR (Muscarinic acetylcholine receptors)Acetylcholinesterase

Beyond the preview

Go deeper on donepezil + scopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + scopolamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call